Overview

To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Must have met the inclusion criteria for the preceding double-blind BID study in
painful diabetic peripheral neuropathy

- Must have received pregabalin/placebo under double-blind conditions for a minimum of 3
weeks.

Exclusion Criteria:

- Patients may not participate if they experienced a serious adverse event during the
preceding double-blind BID study which was determined to be related to the study
medication.